APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antisense and RNAi Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antisense and RNAi Therapeutics Market Outlook and Growth Opportunities 2026

21 December 2025197 pages

Choose your research edition.

Industry ResearchAntisense and RNAi Therapeutics Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Antisense and RNAi Therapeutics Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Antisense and RNAi Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antisense and RNAi Therapeutics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Antisense and RNAi Therapeutics Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Antisense and RNAi Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antisense and RNAi Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antisense and RNAi Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antisense and RNAi Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antisense and RNAi Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antisense and RNAi Therapeutics market include Roche, Tekmira Pharmaceuticals, Sirnaomics, Silence Therapeutics, Santaris, Isis Pharmaceuticals, Arbutus Biopharma, Antisense Therapeutics and Alnylam Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Antisense and RNAi Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antisense and RNAi Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antisense and RNAi Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Antisense and RNAi Therapeutics market.

Antisense and RNAi Therapeutics Segment by Company

Roche

Tekmira Pharmaceuticals

Sirnaomics

Silence Therapeutics

Santaris

Isis Pharmaceuticals

Arbutus Biopharma

Antisense Therapeutics

Alnylam Pharmaceuticals

Antisense and RNAi Therapeutics Segment by Type

RNA Interference

Antisense RNA

Antisense and RNAi Therapeutics Segment by Application

Hospital

Clinic

Antisense and RNAi Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Antisense and RNAi Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Antisense and RNAi Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Antisense and RNAi Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Antisense and RNAi Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antisense and RNAi Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Antisense and RNAi Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense and RNAi Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antisense and RNAi Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense and RNAi Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antisense and RNAi Therapeutics industry.

Chapter 3: Detailed analysis of Antisense and RNAi Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Antisense and RNAi Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Antisense and RNAi Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antisense and RNAi Therapeutics Industry Trends Table 2. Antisense and RNAi Therapeutics Industry Drivers Table 3. Antisense and RNAi Therapeutics Industry Opportunities and Challenges Table 4. Antisense and RNAi Therapeutics Industry Restraints Table 5. Global Antisense and RNAi Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antisense and RNAi Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Antisense and RNAi Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Antisense and RNAi Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Antisense and RNAi Therapeutics Company, Product Type & Application Table 10. Global Antisense and RNAi Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Antisense and RNAi Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of RNA Interference Table 15. Significant Companies of Antisense RNA Table 16. Global Antisense and RNAi Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Antisense and RNAi Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Antisense and RNAi Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Antisense and RNAi Therapeutics Sales Value Share by Type (2021-2026) Table 20. Global Antisense and RNAi Therapeutics Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Global Antisense and RNAi Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Antisense and RNAi Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Antisense and RNAi Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Antisense and RNAi Therapeutics Sales Value Share by Application (2021-2026) Table 27. Global Antisense and RNAi Therapeutics Sales Value Share by Application (2027-2032) Table 28. Global Antisense and RNAi Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Antisense and RNAi Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Antisense and RNAi Therapeutics Sales Value Share by Region (2021-2026) Table 31. Global Antisense and RNAi Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Antisense and RNAi Therapeutics Sales Value Share by Region (2027-2032) Table 33. Global Antisense and RNAi Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Antisense and RNAi Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Antisense and RNAi Therapeutics Sales Value Market Share by Country (2021-2026) Table 36. Global Antisense and RNAi Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Antisense and RNAi Therapeutics Sales Value Market Share by Country (2027-2032) Table 38. Roche Company Information Table 39. Roche Business Overview Table 40. Roche Antisense and RNAi Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Roche Antisense and RNAi Therapeutics Product Portfolio Table 42. Roche Recent Development Table 43. Tekmira Pharmaceuticals Company Information Table 44. Tekmira Pharmaceuticals Business Overview Table 45. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product Portfolio Table 47. Tekmira Pharmaceuticals Recent Development Table 48. Sirnaomics Company Information Table 49. Sirnaomics Business Overview Table 50. Sirnaomics Antisense and RNAi Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Sirnaomics Antisense and RNAi Therapeutics Product Portfolio Table 52. Sirnaomics Recent Development Table 53. Silence Therapeutics Company Information Table 54. Silence Therapeutics Business Overview Table 55. Silence Therapeutics Antisense and RNAi Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Silence Therapeutics Antisense and RNAi Therapeutics Product Portfolio Table 57. Silence Therapeutics Recent Development Table 58. Santaris Company Information Table 59. Santaris Business Overview Table 60. Santaris Antisense and RNAi Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Santaris Antisense and RNAi Therapeutics Product Portfolio Table 62. Santaris Recent Development Table 63. Isis Pharmaceuticals Company Information Table 64. Isis Pharmaceuticals Business Overview Table 65. Isis Pharmaceuticals Antisense and RNAi Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Isis Pharmaceuticals Antisense and RNAi Therapeutics Product Portfolio Table 67. Isis Pharmaceuticals Recent Development Table 68. Arbutus Biopharma Company Information Table 69. Arbutus Biopharma Business Overview Table 70. Arbutus Biopharma Antisense and RNAi Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Arbutus Biopharma Antisense and RNAi Therapeutics Product Portfolio Table 72. Arbutus Biopharma Recent Development Table 73. Antisense Therapeutics Company Information Table 74. Antisense Therapeutics Business Overview Table 75. Antisense Therapeutics Antisense and RNAi Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Antisense Therapeutics Antisense and RNAi Therapeutics Product Portfolio Table 77. Antisense Therapeutics Recent Development Table 78. Alnylam Pharmaceuticals Company Information Table 79. Alnylam Pharmaceuticals Business Overview Table 80. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product Portfolio Table 82. Alnylam Pharmaceuticals Recent Development Table 83. Research Programs/Design for This Report Table 84. Authors List of This Report Table 85. Secondary Sources Table 86. Primary Sources List of Figures Figure 1. Antisense and RNAi Therapeutics Product Image Figure 2. Global Antisense and RNAi Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antisense and RNAi Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Antisense and RNAi Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. RNA Interference Image Figure 8. Antisense RNA Image Figure 9. Global Antisense and RNAi Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Antisense and RNAi Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Antisense and RNAi Therapeutics Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Global Antisense and RNAi Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Antisense and RNAi Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Antisense and RNAi Therapeutics Sales Value Share by Application (2021-2032) Figure 17. Global Antisense and RNAi Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Antisense and RNAi Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Antisense and RNAi Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 20. North America Antisense and RNAi Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Antisense and RNAi Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Antisense and RNAi Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Antisense and RNAi Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Antisense and RNAi Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Antisense and RNAi Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 26. South America Antisense and RNAi Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Antisense and RNAi Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Antisense and RNAi Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • RNA Interference
  • Antisense RNA
Applications
  • Hospital
  • Clinic
Companies covered
  • Roche
  • Tekmira Pharmaceuticals
  • Sirnaomics
  • Silence Therapeutics
  • Santaris
  • Isis Pharmaceuticals
  • Arbutus Biopharma
  • Antisense Therapeutics
  • Alnylam Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antisense and RNAi Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antisense and RNAi Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Antisense and RNAi Therapeutics Market Dynamics
  1. 2.1 Antisense and RNAi Therapeutics Industry Trends
  2. 2.2 Antisense and RNAi Therapeutics Industry Drivers
  3. 2.3 Antisense and RNAi Therapeutics Industry Opportunities and Challenges
  4. 2.4 Antisense and RNAi Therapeutics Industry Restraints
3 Antisense and RNAi Therapeutics Market by Company
  1. 3.1 Global Antisense and RNAi Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Antisense and RNAi Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Antisense and RNAi Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Antisense and RNAi Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Antisense and RNAi Therapeutics Company Product Type and Application
  6. 3.6 Global Antisense and RNAi Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Antisense and RNAi Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Antisense and RNAi Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Antisense and RNAi Therapeutics Market by Type
  1. 4.1 Antisense and RNAi Therapeutics Type Introduction
  2. 4.1.1 RNA Interference
  3. 4.1.2 Antisense RNA
  4. 4.2 Global Antisense and RNAi Therapeutics Sales Value by Type
  5. 4.2.1 Global Antisense and RNAi Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Antisense and RNAi Therapeutics Sales Value by Type (2021-2032)
  7. 4.2.3 Global Antisense and RNAi Therapeutics Sales Value Share by Type (2021-2032)
5 Antisense and RNAi Therapeutics Market by Application
  1. 5.1 Antisense and RNAi Therapeutics Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Antisense and RNAi Therapeutics Sales Value by Application
  5. 5.2.1 Global Antisense and RNAi Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Antisense and RNAi Therapeutics Sales Value by Application (2021-2032)
  7. 5.2.3 Global Antisense and RNAi Therapeutics Sales Value Share by Application (2021-2032)
6 Antisense and RNAi Therapeutics Regional Value Analysis
  1. 6.1 Global Antisense and RNAi Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antisense and RNAi Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Antisense and RNAi Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Antisense and RNAi Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antisense and RNAi Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Antisense and RNAi Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Antisense and RNAi Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Antisense and RNAi Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Antisense and RNAi Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Antisense and RNAi Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Antisense and RNAi Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Antisense and RNAi Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Antisense and RNAi Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Antisense and RNAi Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Antisense and RNAi Therapeutics Country-level Value Analysis
  1. 7.1 Global Antisense and RNAi Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antisense and RNAi Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Antisense and RNAi Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Antisense and RNAi Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Antisense and RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Antisense and RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Antisense and RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche
  2. 8.1.1 Roche Company Information
  3. 8.1.2 Roche Business Overview
  4. 8.1.3 Roche Antisense and RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Roche Antisense and RNAi Therapeutics Product Portfolio
  6. 8.1.5 Roche Recent Developments
  7. 8.2 Tekmira Pharmaceuticals
  8. 8.2.1 Tekmira Pharmaceuticals Company Information
  9. 8.2.2 Tekmira Pharmaceuticals Business Overview
  10. 8.2.3 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product Portfolio
  12. 8.2.5 Tekmira Pharmaceuticals Recent Developments
  13. 8.3 Sirnaomics
  14. 8.3.1 Sirnaomics Company Information
  15. 8.3.2 Sirnaomics Business Overview
  16. 8.3.3 Sirnaomics Antisense and RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sirnaomics Antisense and RNAi Therapeutics Product Portfolio
  18. 8.3.5 Sirnaomics Recent Developments
  19. 8.4 Silence Therapeutics
  20. 8.4.1 Silence Therapeutics Company Information
  21. 8.4.2 Silence Therapeutics Business Overview
  22. 8.4.3 Silence Therapeutics Antisense and RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Silence Therapeutics Antisense and RNAi Therapeutics Product Portfolio
  24. 8.4.5 Silence Therapeutics Recent Developments
  25. 8.5 Santaris
  26. 8.5.1 Santaris Company Information
  27. 8.5.2 Santaris Business Overview
  28. 8.5.3 Santaris Antisense and RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Santaris Antisense and RNAi Therapeutics Product Portfolio
  30. 8.5.5 Santaris Recent Developments
  31. 8.6 Isis Pharmaceuticals
  32. 8.6.1 Isis Pharmaceuticals Company Information
  33. 8.6.2 Isis Pharmaceuticals Business Overview
  34. 8.6.3 Isis Pharmaceuticals Antisense and RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Isis Pharmaceuticals Antisense and RNAi Therapeutics Product Portfolio
  36. 8.6.5 Isis Pharmaceuticals Recent Developments
  37. 8.7 Arbutus Biopharma
  38. 8.7.1 Arbutus Biopharma Company Information
  39. 8.7.2 Arbutus Biopharma Business Overview
  40. 8.7.3 Arbutus Biopharma Antisense and RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Arbutus Biopharma Antisense and RNAi Therapeutics Product Portfolio
  42. 8.7.5 Arbutus Biopharma Recent Developments
  43. 8.8 Antisense Therapeutics
  44. 8.8.1 Antisense Therapeutics Company Information
  45. 8.8.2 Antisense Therapeutics Business Overview
  46. 8.8.3 Antisense Therapeutics Antisense and RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Antisense Therapeutics Antisense and RNAi Therapeutics Product Portfolio
  48. 8.8.5 Antisense Therapeutics Recent Developments
  49. 8.9 Alnylam Pharmaceuticals
  50. 8.9.1 Alnylam Pharmaceuticals Company Information
  51. 8.9.2 Alnylam Pharmaceuticals Business Overview
  52. 8.9.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product Portfolio
  54. 8.9.5 Alnylam Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst